Dermapharm Holding Debt 2025

Dermapharm Holding Aktienanalyse

What does Dermapharm Holding do?

Dermapharm Holding SE is a German company specializing in the development, manufacturing, and distribution of pharmaceuticals and skincare products. It was founded in 1991 by Dr. Hans-Georg Feldmeier and is headquartered in Grünwald near Munich. Dermapharm is a publicly traded company and has experienced impressive growth in recent years. It operates in the German market for prescription and over-the-counter drugs and also has a wide portfolio of skincare products for various applications. The business model of Dermapharm focuses on the development of new pharmaceuticals and skincare products to meet the needs of patients and consumers. The company maintains a highly scientific research and development department working on innovative therapies and care products. Dermapharm operates in various segments, including dermatological and ophthalmological therapeutics, women and children's health, urology, self-medication, and skincare. The company also offers a wide range of generic products. Some of Dermapharm's well-known products include Acnatac, a combination of Tretinoin and Clindamycin for the treatment of acne, and the gynecological therapy product line Gynofit, which is designed for the treatment of vaginal infections and irritations in women. Furthermore, Dermapharm has developed a comprehensive range of skincare products under its brand Linola. Linola is a brand that focuses on the care of atopic skin, neurodermatitis, and other skin conditions. Linola products are also available in various textures, including lotions, creams, and oils. Over the years, Dermapharm has established a strong presence in the European market and operates in more than 50 countries worldwide. The company also collaborates with external partners and promoters to successfully market its brands and products. Overall, Dermapharm has experienced strong growth thanks to its scientific approach and strong distribution network. The company remains committed to developing new therapies and products to meet the needs of patients and consumers, and to expand its presence on an international level. Dermapharm Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Dermapharm Holding's Debt Structure

Dermapharm Holding's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Dermapharm Holding's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Dermapharm Holding’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Dermapharm Holding’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Dermapharm Holding stock

What is the debt of Dermapharm Holding this year?

Dermapharm Holding has a debt level of 948.36 EUR this year.

What was the debt of Dermapharm Holding compared to the previous year?

The debt of Dermapharm Holding has increased by 2.9% compared to the previous year increased.

What are the consequences of high debt for investors in Dermapharm Holding?

High debt can pose a risk for investors of Dermapharm Holding, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Dermapharm Holding?

Low debt means that Dermapharm Holding has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Dermapharm Holding affect the company?

An increase in debt of Dermapharm Holding can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Dermapharm Holding affect the company?

A reduction in debt of Dermapharm Holding can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Dermapharm Holding?

Some factors that can influence the debt of Dermapharm Holding include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Dermapharm Holding so important for investors?

The debts of Dermapharm Holding are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Dermapharm Holding take to change the debt?

To change the debt, Dermapharm Holding can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Dermapharm Holding pay?

Over the past 12 months, Dermapharm Holding paid a dividend of 0.88 EUR . This corresponds to a dividend yield of about 2.57 %. For the coming 12 months, Dermapharm Holding is expected to pay a dividend of 0.97 EUR.

What is the dividend yield of Dermapharm Holding?

The current dividend yield of Dermapharm Holding is 2.57 %.

When does Dermapharm Holding pay dividends?

Dermapharm Holding pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Dermapharm Holding?

Dermapharm Holding paid dividends every year for the past 0 years.

What is the dividend of Dermapharm Holding?

For the upcoming 12 months, dividends amounting to 0.97 EUR are expected. This corresponds to a dividend yield of 2.84 %.

In which sector is Dermapharm Holding located?

Dermapharm Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dermapharm Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dermapharm Holding from 7/1/2025 amounting to 0.9 EUR, you needed to have the stock in your portfolio before the ex-date on 6/27/2025.

When did Dermapharm Holding pay the last dividend?

The last dividend was paid out on 7/1/2025.

What was the dividend of Dermapharm Holding in the year 2024?

In the year 2024, Dermapharm Holding distributed 1.05 EUR as dividends.

In which currency does Dermapharm Holding pay out the dividend?

The dividends of Dermapharm Holding are distributed in EUR.